【レポートの概要（一部）】
1. Report Summary
1.1 Leading Contract Manufacturing Organisations (CMOs) Review
1.2 Leading CMOs – Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers Information
1.5 Main Questions This Report Answers
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQs)
1.9 Some Related Reports
1.10 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2014
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2013
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2014-2024
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2014-2024
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2014-2024
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2014-2024
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?
3. Leading European Contract Manufacturing Organisations (CMOs), 2014
3.1 Lonza
3.1.1 Lonza Is a Leader in Biologics Manufacturing
3.1.2 Lonza Contract Manufacturing and Development: Declining Revenue, but Increased Efficiency, 2009-2013
3.1.3 Investing in Advanced Biological Drug Sectors
3.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
3.1.5 Lonza and Regenerative Medicine
3.1.6 Lonza: SWOT Analysis 2014-2024
3.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2014-2024
3.1.8 Lonza: Company Insight
3.2 Evonik Degussa
3.2.1 Investing in API and Drug Delivery Services
3.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2009-2013
3.2.3 Evonik Is a HPAPI Specialist
3.2.4 Evonik Continues to Grow Across All Segments
3.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
3.2.6 Evonik Degussa: Revenue Forecast 2014-2024
3.3 Royal DSM
3.3.1 Marginal Revenue Growth and Rapidly Declining Operating Profit in Pharma Manufacturing 2009-2013
3.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2009-2013
3.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
3.3.4 DPx Holdings: A New Leader in the CMO Market
3.3.5 Investing in Biopharma Manufacturing
3.3.6 Expanding API Manufacturing
3.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2024
3.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2014-2024
3.4 Boehringer Ingelheim Contract Manufacturing
3.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
3.4.2 Production Through to Fill and Finished Biopharmaceuticals
3.4.3 A Track Record of Production for 28 Biopharma Products
3.4.4 Declining Revenue from Contract Manufacturing, 2009-2013
3.4.5 Pulling Out of Small Molecule API Manufacturing
3.4.6 Expanding through New Services
3.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2014-2024
3.4.8 Boehringer Ingelheim: Revenue Forecast 2014-2024
3.4.9 Boehringer Ingelheim Biopharmaceuticals: Company Insight
3.5 Fareva
3.5.1 Fareva Has 35 Years’ Manufacturing Experience
3.5.2 Revenue Growth through Acquisitions: 2009-2013
3.5.3 Fareva SWOT Analysis: 2014-2024
3.5.4 Fareva Revenue Forecast: 2014-2024
3.6 Aenova Group
3.6.1 Acquisition of Haupt Creates European CMO Goliath
3.6.2 Aenova’s Ever Expanding Manufacturing Capacity
3.6.3 Aenova’s Revenue 2009-2013: Organic Growth and Acquisitions
3.6.4 Haupt Pharma Acquisition: Revenue Growth 2009-2013
3.6.5 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.6.6 Becoming a Leading Contract Manufacturer: Aenova Revenue and Operation Profit Forecast 2014-2024
3.7 Famar
3.7.1 Famar Is an Expert in Lyophilisation
3.7.2 Sustained Growth in Famar’s Revenue: 2009-2013
3.7.3 Expanding European Operations
3.7.4 Further Site Acquisitions Are an Opportunity for Growth 2014-2024
3.7.5 How Will Famar Perform 2014-2024?
3.8 Vetter Pharma
3.8.1 Vetter is an Injectable Manufacturing Specialist
3.8.2 Rapidly Growing Revenue in the US and Germany: 2009-2013
3.8.3 Services, Collaborations and Differentiating Factors
3.8.4 Biologics Are an Opportunity for Growth for Vetter 2014-2024
3.8.5 Vetter Outlook: Revenue Forecast 2014-2024
3.9 Almac Group
3.9.1 Almac’s Manufacturing Services
3.9.2 Almac Outpaces the Market: 2009-2013
3.9.3 Almac Adds Capacity in the UK and US
3.9.4 New Services Added 2012-2014
3.9.5 Almac Group: Contract Manufacturing Market Outlook 2014-2024
3.9.6 How Will Almac Group Perform 2014-2024?
3.10 Delpharm
3.10.1 Finished Dosage Form Manufacturing for Developed Markets
3.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2009-2013
3.10.3 Delpharm: Outlook and Prospects for Growth 2014-2024
3.10.4 Generics Will Drive Revenue Growth for Delpharm 2014-2024
3.11 Siegfried
3.11.1 Expanding Siegfried’s Manufacturing Footprint
3.11.2 Siegfried: Financial Performance 2009-2013
3.11.3 Expanding High Potency API Capabilities
3.11.4 Expanding Into China 2013-2014
3.11.5 Siegfried’s Characteristics Within the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.11.6 Continued Revenue Growth for Siegfried 2014-2024
3.12 Corden Pharmaceutical
3.12.1 CordenPharma Has Grown through Acquisitions
3.12.2 Corden Pharmaceutical: SWOT Analysis 2014-2024
3.13 Recipharm
3.13.1 Contract Development and Manufacturing Services
3.13.2 Recipharm: Financial Performance 2009-2013
3.13.3 Recipharm Invests in Facility Expansion
3.13.4 Recipharm: Opportunities for Growth 2014-2024
3.13.5 Outlook for Recipharm: Revenue Forecast 2014-2024
3.13.6 Recipharm: Company Insight
3.14 Aesica Pharmaceuticals
3.14.1 Aesica Manufactures APIs and Finished Dosage Forms
3.14.2 Acquisitions Drive Revenue Growth But Operational Margins Have Declined, 2009-2013
3.14.3 Partnering with Academia for Innovative Solutions
3.14.4 Growth through Acquisitions and Internal Expansion
3.14.5 Aesica: Opportunities for Expansion 2014-2024
3.14.6 Forecast Aesica Financial Performance, 2014-2024
4. Other Leading Developed-Market CMOs, 2014
4.1 Catalent Pharma Solutions Is the World’s Largest CMO
4.1.1 Catalent: Manufacturing Services and Capabilities
4.1.2 Divisional Segmentation – Breaking Down Catalent’s Service
4.1.3 Revenue Growth with Improved Operational Margins: Catalent Pharma’s Performance, 2009-2013
4.1.4 Sustained Grow in Oral Products and Development Services: Catalent Pharma’s Divisional Performance, 2009-2013
4.1.5 Catalent Is Expanding its Oral Technologies Division
4.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
4.1.7 Adding New Early-Stage Development Services
4.1.8 Expansion in Japan – Growth Prospects for Catalent
4.1.9 New Business Contracts 2013-2014
4.1.10 Catalent: Opportunities for Growth 2014-2024
4.1.11 Catalent: Mild Growth in Revenue and Operating Profit 2014-2024
4.2 Patheon – FDF Manufacturer and Drug Development Services
4.2.1 Patheon – Global leader in Pharmaceutical Development Services
4.2.2 Contract Manufacturing Services at Patheon
4.2.3 Steady Revenue Growth 2009-2013
4.2.4 Formation of DPx Holdings
4.2.5 Adding New Formulations and Formulation Development Services
4.2.6 Reassessing Manufacturing Capacity
4.2.7 Patheon: SWOT Analysis 2014-2024
4.2.8 Patheon: Contract Manufacturing Revenue Forecast 2014-2024
4.2.9 Patheon: Company Insight
4.3 Baxter BioPharma Solutions
4.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
4.3.2 Historic Revenue Performance 2009-2013
4.3.3 Baxter BioPharma SWOT Analysis 2014-2024
4.3.4 Baxter BioPharma Revenue Forecast 2014-2024
4.4 Nipro Corporation: Japan’s Leading CMO
4.4.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
4.4.2 Nipro: Exceptional Growth in Revenue and Operating Profits 2009-2013
4.4.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2014-2024
4.4.4 Nipro Revenue and Profitability Forecast 2014-2014
4.5 AbbVie Contract Manufacturing
4.5.1 AbbVie Offers Full-Service Contract Manufacturing
4.5.2 Expanding and Adding New Services: 2013-2014
4.5.3 AbbVie Contract Manufacturing: Revenue 2011-2013
4.5.4 Biologics and HPAPIs Are an Opportunity for Growth 2014-2024
4.5.5 AbbVie Contract Manufacturing Revenue Forecast 2014-2024
4.5.6 AbbVie Contract Manufacturing: Company Insight
4.6 Daito Pharmaceutical
4.6.1 Daito Has a Portfolio of More than 30 APIs
4.6.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2009-2013
4.6.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2014-2024
4.6.4 Sustained Growth in Revenue and Operating Profit for Daito, 2014-2024
4.7 Pfizer CentreSource
4.7.1 Pfizer CentreSource: Historic Revenue Performance, 2009-2013
4.7.2 Will Pfizer Divest CentreSource?
4.7.3 Outlook for CentreSource: Revenue Forecast 2014-2024
5. Leading Developed Market API Manufacturers, 2014
5.1 Teva API
5.1.1 API Manufacturing Services
5.1.2 Teva API: Financial Performance 2009-2013
5.1.3 Building a Footprint in Mexico, India and China
5.1.4 Teva API: SWOT Analysis 2014-2024
5.1.5 Outlook for Teva API: Revenue Forecast 2014-2024
5.2 Esteve Química
5.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
5.2.2 Investing to Expand 2004-2013
5.2.3 Esteve Química: SWOT Analysis 2014-2024
5.3 Euticals
5.3.1 Euticals Manufactures More than 200 APIs
5.3.2 Acquisitions Drive Growth 2009-2013
5.3.3 Adding Capacity for Finished Dosage Forms
5.3.4 Asian Expansion Is an Opportunity for Growth 2014-2024
5.3.5 Euticals: Revenue Forecast 2014-2024
6. Leading Chinese Pharmaceutical Contract Manufacturers, 2014
6.1 Zhejiang Hisun Pharmaceutical
6.1.1 API Manufacturing for Markets Worldwide
6.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2009-2013
6.1.3 Moving Into International Drug Marketing
6.1.4 Zhejiang Hisun: Opportunities for Growth 2014-2024
6.1.5 Zhejiang Hisun: Strong API Revenue Growth 2014-2024
6.2 Zhejiang Huahai Pharmaceuticals
6.2.1 Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
6.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2009-2013
6.2.3 Expanding in the US Generic Drugs Market
6.2.4 Zhejiang Huahai: SWOT Analysis, 2014
6.2.5 Zhejiang Huahai: Revenue Forecast, 2014-2024
6.3 Shandong Xinhua Pharmaceutical
6.3.1 Experience in APIs and Finished Dosage Forms
6.3.2 Shandong Xinhua: Strong Revenue Growth 2009-2013
6.3.3 Growing through Joint Ventures
6.3.4 Looking to Expand in the US and EU 2014-2024
6.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2014-2024
7. Leading Indian Pharmaceutical Contract Manufacturers, 2014
7.1 Aurobindo Pharma
7.1.1 API Manufacturing Services
7.1.2 Aurobindo Pharma: Steady Revenue Growth 2009-2013
7.1.3 Aurobindo Expanding Outside of Antibacterials
7.1.4 Aurobindo: Opportunities for Expansion 2014-2024
7.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2014-2024?
7.2 Divis Laboratories
7.2.1 Divis Laboratories and the Contract Manufacturing Industry
7.2.2 Divis Laboratories: The Fastest Growing CMO 2009-2013
7.2.3 Divis Laboratories: API Manufacturing Outlook 2014-2024
7.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2014-2024
7.3 Dr. Reddy’s Laboratories
7.3.1 API and FDF Manufacturing Services
7.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2009-2013
7.3.3 Advancing in Complex Drug Manufacturing
7.3.4 Expanding in the European Manufacturing Market
7.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2014-2024
8. Conclusions to Our Study
8.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
8.2 Strategies for Growth: Prospects for Leading CMOs, 2014-2024
8.3 High Demand for Biopharmaceutical Manufacturing Services
8.4 Investing in Novel Technologies
8.5 Outlook for API Manufacturers
【レポート販売概要】
■ タイトル：医薬品有力企業シリーズ：主要医薬品製造受託機関(CMO)分析■ 英文：Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024
■ 発行日：2014年9月
■ 調査会社：visiongain
■ 商品コード：VISION411062
■ 調査対象地域：グローバル
- リモコンの世界市場2016-2020About Remote Remotes/remote controls are devices used to wirelessly operate electronic gadgets such as TVs (including smart TVs), set-top boxes, and gaming consoles from a short line-of-sight distance. Users typically use a remote to adjust various settings such as tracking number and volume. There are two popular types of remote controls mostly used by customers: IR remotes and RF remotes. IR rem …
- 糖尿病性眼疾患用デバイスの世界市場：硝子体切除術パック、網膜レーザー、硝子体切除機械About Diabetic Eye Disease Devices Diabetes eye diseases consist of a group of eye-related conditions that affect individuals with diabetes. The conditions include diabetic macular edema (DME), diabetic retinopathy, glaucoma, and cataract. Diabetes is the leading cause of eye diseases and can cause severe vision loss or blindness. These eye diseases are widely treated with laser surgery. Technavio …
- クラウドDLPの世界市場予測（～2022年）：ソリューション、サービスThe increasing need to prevent critical data from getting leaked is expected to be driving the cloud Data Loss Prevention (DLP) market growthThe cloud DLP market is expected to grow from USD 744.4 million in 2017 to USD 2,508.9 million by 2022, at a Compound Annual Growth Rate (CAGR) of 27.5%. The market is said to be driven by various factors, such as the achievement of regulatory compliances and …
- 世界の物理セキュリティー市場：ビデオ監視、アクセスコントロール、生体認証、侵入検知、セキュリティシステムなどThe security concerns for personnel, information, hardware, and network infrastructure increased the demand for innovative physical security products. The adoption of Internet Protocol (IP) video network, sophisticated access control systems and monitoring solutions, such as Physical Security Information Management (PSIM) will drive the market in the near future. The demand is huge in the emerging …
- テレラジオロジー（遠隔放射線診断）の世界市場2016-2020About the Global Teleradiology Market The healthcare industry is witnessing phenomenal changes owing to increased adoption of digital health platforms such as mobile health, telehealth, EMR, and other wireless technologies. Digital health platforms have become essential elements in every healthcare organization, as they enable remote monitoring of patients, increase healthcare delivery efficiencie …
- 分子診断のグローバル市場：新技術、最新検査、市場予測、競争優位This new seven-country study from Venture Planning Group contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. Highlights- Business and technological trends in seven major markets: France, Germany, Italy, Japa …
- 黄斑変性症（AMD）及びその他の網膜疾患治療薬の世界市場AMD and Other Retinal Diseases – our new study reveals trends, R&D progress, and predicted revenuesWhere is the AMD and Other Retinal Diseases market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our …
- 球様細胞白質萎縮症(クラッベ病)治療のグローバル臨床試験動向（2014年H1）Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2014" provides data on the Globoid Cell Leukodystrophy (Krabbe Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Globoi …
- フレキシブルプラスチック包装の世界市場予測（～2022年）：ポーチ、袋、ラップ、ロールストック、プレスチックフィルム、紙、アルミ箔、 バイオプラスチック“Growth in demand from the food & beverage industry to drive the market for flexible plastic packaging” The global market for flexible plastic packaging is projected to grow from USD 102.19 billion in 2017 to reach USD 131.65 billion by 2022, at an estimated CAGR of 5.2%. The flexible plastic packaging market is driven by factors such as growth in demand for sustainable packaging, increase in the …
- エッグトレーの世界市場2017-2021About Egg TrayEgg trays are mainly used for transportation and storage. They are built in such a way that they can be stacked, which facilitates bulk transportation. Such trays are mainly used by poultry farmers or wholesalers to transport eggs in bulk for retailers. The size of egg trays carrying eggs may vary depending on factors such as distance and the type of product offering. Technavio’s ana …
- レーザー・フィルタ保護（安全ゴーグル）の世界市場2016-2020About Laser Filter Laser filter protection or laser safety goggles are used to protect workers from exposure to lasers during manufacturing, laboratory processes, and others. Depending on the type of laser, different types of laser filter protection are used. Technavio’s analysts forecast the global laser filter protection market to grow at a CAGR of 5.50% during the period 2016-2020. [Covered in …
- 無線周波数（RF）信号発生器の世界市場展望2017-20276According to Stratistics MRC, the Global Radio Frequency (RF) Signal Generator Market is accounted for $24.43 million in 2017 and is expected to reach $33.30 million by 2026 growing at a CAGR of 3.5% during the forecast period. Increasing demand for rental test equipment and rising interest in LTE-A in rural zones are some of the factors fuelling the market growth. However, large space requirement …
- 世界のケミカル中間体市場2015The Global Chemical Intermediates Industry Report 2015 is a professional and in-depth study on the current state of the Chemical Intermediates industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Chemical Intermediates market analysis is provided for the international markets including development tren …
- ワイヤーラインサービスの世界市場This report forecasts the wireline services market in terms of value in USD Million ($ Million). This has been segment into component regions, which has been further split into countries. The oil and gas industry witnessed high growth in the oilfield services since the financial crisis in 2009 as the oil and gas production increased and the oil prices remained well over $100/barrel. This changed i …
- 世界の無線ネットワークインフラ市場（2014 – 2020）The term “Wireless Network Infrastructure” has conventionally been associated with macrocell Radio Access Network (RAN) and mobile core network infrastructure, which SNS Research estimates to account for nearly $52 Billion in spending by the end of 2014. However, the scope of the term is expanding as wireless carriers increase their investments in Heterogeneous Network or HetNet infrastructure enc …
